Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 80 EUR
  • 25 mg - 320 EUR
  • 100 mg - 960 EUR

Intedanib

Intedanib is a kinase inhibitor blocking VEGFR, PDGFR and FGFR receptors, developed for the treatment of several malignancies and idiopathic pulmonary fibrosis. Intedanib also significantly decreased blood vessel area in treated tumours. The sustained inhibition of VEGFR phosphorylation, the fast in vivo clearance and clinical efficacy against a broad range of malignancies appear to be the major advantages of intedanib. Furthermore, the existing data suggest an excellent safety profile. As of 2012, intedanib undergoes several phase III trials for the treatment of NSCLC and ovarian cancer.

catalogue number: I144
synonyms: BIBF1120, Nintedanib, Vargatef
CAS: 656247-17-5
MW: 539.62 g/mol

References
J Med Chem. 2009 Jul 23;52(14):4466-80. PMID: 19522465
IDrugs. 2010 May;13(5):332-45. PMID: 20432191